Mednet Logo

In LS-SCLC, for a patient with positive mediastinal LN but PET negative ipsilateral hilum, would you treat the hilum?

If so, would you treat to full dose or lower elective dose?
5 Answers
Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · Beaumont Health System
Answered on

I generally agree with Dr. @Dr. First Last, however, it would depend on the location of the primary tumor. If the dose to the primary treated part of the hilum, I would treat the hilum more comprehensively. This just because it would be so difficult to go back should the tumor fail there. I agree th...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Radiation Oncology · Michigan Healthcare Professionals, PC
Answered on

No. With PET staging, there is a low rate of isolated nodal failure and at this point in time, I would only treat the positive areas. A prospective study from the Dutch studied this and found just 3% failure rate.

That being said, elective nodal irradiation with more conformal fields (VMAT) may not ...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Radiation Oncology · USC Keck School of Medicine
Answered on

It's rare for SCLC to not involve the hilum somehow. For example, I would feel uneasy skipping the negative hilum for a central-ish tumor with Lv 4 involved. In the 3D era, the hilum for sure got dosed, and it's counterintuitive to intentionally cool down the hilum with IMRT when the tumor most like...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Radiation Oncology · Bismarck Cancer Center
Answered on

Playing a bit of devil's advocate in favor of not electively covering (nor purposely avoiding) the ipsilateral hilar region, a couple of additional points to consider, though by no means authoritative guideline:

- Direct lung parenchyma-to-mediastinal lymphatic drainage patterns, bypassing the hilar ...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Radiation Oncology · UP Health System, Marquettte
Answered on

The recently published "High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with LSSCLC: an open label, randomized, phase 2 trial" (Grønberg et al., PMID 33662285) is, to me, the most significant publication regarding radiation therapy for this disease recently. They treate...

Join for free or sign in to see the full answer